Acupoint catgut embedding advantage in treating gastro-oesophageal reflux disease (ACE-GERD): study protocol for a randomised controlled trial

被引:0
|
作者
Wen, Shuting [1 ]
Zhao, Xiying [1 ]
Lin, Xiaofeng [1 ]
Fu, Zhaoli [1 ]
Qin, Shumin [1 ]
Pan, Qimou [1 ]
Liu, Fengbin [2 ]
He, Wenfang [1 ]
Liu, Tianwen [1 ]
机构
[1] Guangzhou Univ Chinese Med, Dept Gastroenterol, Affiliated Hosp 2, Guangzhou, Guangdong, Peoples R China
[2] Guangzhou Univ Tradit Chinese Med, Dept Gastroenterol, Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R China
来源
BMJ OPEN | 2024年 / 17卷 / 10期
关键词
Gastroenterology; Anxiety disorders; Depression & mood disorders; PUMP INHIBITORS; ACUPUNCTURE; DEPRESSION; MECHANISMS; THERAPY; ANXIETY;
D O I
10.1136/bmjopen-2023-081059
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Gastro-oesophageal reflux disease (GERD) is a highly prevalent disorder worldwide and developing effective treatment strategies for GERD is a clinical priority. GERD is associated with anxiety and depression. Several approaches have been developed to improve GERD, although effectiveness is limited. Acupoint catgut embedding (ACE) is an established technique in traditional Chinese medicine for the treatment of anxiety and depression. This study will investigate the effects of ACE on anxiety, depression, acid reflux and heartburn in patients with GERD. Methods The ACE-GERD trial is a single-centre, prospective randomised controlled trial. 62 patients will be randomly assigned equally to the experimental and control groups. Patients will be treated with ACE or sham ACE. In the experimental group, absorbable polyglycolic acid sutures will be implanted at the acupoints using sterile disposable injection needles. The sham ACE treatment will exhibit similar surface characteristics but lack absorbable polyglycolic acid sutures. Treatments will be administered every 2 weeks for a period of 10 weeks. The main outcome measure is the Reflux Disease Questionnaire symptom score. Secondary outcomes are the endoscopic assessment, 24-hour pH/impedance monitoring test, oesophageal high-resolution manometer, Gastro-oesophageal Reflux Disease Questionnaire score, Gastro-oesophageal Reflux Disease Health-related Quality of Life, Self-rating Anxiety Scale and Self-rating Depression Scale scores. Discussion The ACE-GERD trial aims to evaluate the efficacy of ACE treatment as a therapeutic tool for improving anxiety, depression, acid reflux and heartburn in patients with GERD and to provide the evidence base for future clinical studies. Ethics and Dissemination The trial has been approved by the Ethics Committee of Guangdong Provincial Hospital of Chinese Medicine (ethics no. BF2023-113-01). Results will be published in peer-reviewed journals and presented at scientific conferences and meetings.
引用
收藏
页数:7
相关论文
共 50 条
  • [31] Indirect comparison of randomised controlled trials: comparative efficacy of dexlansoprazole vs. esomeprazole in the treatment of gastro-oesophageal reflux disease
    Wu, M. S.
    Tan, S. C.
    Xiong, T.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2013, 38 (02) : 190 - 201
  • [32] Laparoscopic partial posterior vs. total fundoplication in gastro-oesophageal reflux disease (GERD) with oesophageal dismotility, short term results of a prospective study
    Ferulano, GP
    La Manna, S
    Dilillo, S
    Forgione, A
    Vanni, L
    Brunaccino, R
    Lionetti, R
    D'Ambra, M
    E.A.E.S: PROCEEDINGS OF THE 8TH INTERNATIONAL CONGRESS OF THE EUROPEAN ASSOCIATION FOR ENDOSCOPIC SURGERY, 2000, : 315 - 320
  • [33] Prospective randomised trial of laparoscopic Nissen fundoplication versus maintenance proton pump inhibition in the treatment of gastro-oesophageal reflux disease
    Mahon, D
    Decadt, B
    Lowndes, RH
    Beckingham, I
    Rhodes, M
    GASTROENTEROLOGY, 2002, 122 (04) : A67 - A67
  • [34] Trial of transcutaneous electrical acupoint stimulation in laryngopharyngeal reflux disease: study protocol for a randomized controlled trial
    Hailong Shen
    Yanxun Han
    Di Wu
    Lihong Hu
    Yunxia Ma
    Feihu Wu
    Ye Tao
    Yehai Liu
    Trials, 23
  • [35] Trial of transcutaneous electrical acupoint stimulation in laryngopharyngeal reflux disease: study protocol for a randomized controlled trial
    Shen, Hailong
    Han, Yanxun
    Wu, Di
    Hu, Lihong
    Ma, Yunxia
    Wu, Feihu
    Tao, Ye
    Liu, Yehai
    TRIALS, 2022, 23 (01)
  • [36] Randomised, controlled, crossover study to assess the suppression of gastro-oesophageal reflux (GOR) by sodium alginate formulations in the form of liquid and tablets
    Thomas, E. C. M.
    Sykes, J.
    Berry, P.
    Strugala, V.
    Dettmar, P. W.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2010, 25 : A126 - A126
  • [37] Clinical trial: chest pain caused by presumed gastro-oesophageal reflux in coronary artery disease - controlled study of lansoprazole vs. placebo
    Talwar, V.
    Wurm, P.
    Bankart, M. J. G.
    Gershlick, A. H.
    de Caestecker, J. S.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2010, 32 (02) : 191 - 199
  • [38] Cardiac mucosa at the gastro-oesophageal junction: indicator of gastro-oesophageal reflux disease? Data from a prospective central European multicentre study on histological and endoscopic diagnosis of oesophagitis (histoGERD trial)
    Langner, Cord
    Schneider, Nora I.
    Plieschnegger, Wolfgang
    Schmack, Bertram
    Bordel, Hartmut
    Hoefler, Bernd
    Eherer, Andreas J.
    Wolf, Eva-Maria
    Rehak, Peter
    Vieth, Michael
    HISTOPATHOLOGY, 2014, 65 (01) : 81 - 89
  • [39] Prevalence of gastro-oesophageal reflux disease (GERD) and manometric oesophageal finding in patients with morbid obesity selected for bariatric surgery. A prospective study in 100 patients
    Merrouche, M
    Harnois, F
    Sabate, JM
    Msika, S
    Coffin, B
    GASTROENTEROLOGY, 2004, 126 (04) : A328 - A329
  • [40] Randomised clinical trial: effects of monotherapy with ADX10059, a mGluR5 inhibitor, on symptoms and reflux events in patients with gastro-oesophageal reflux disease
    Zerbib, F.
    des Varannes, S. Bruley
    Roman, S.
    Tutuian, R.
    Galmiche, J. -P.
    Mion, F.
    Tack, J.
    Malfertheiner, P.
    Keywood, C.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2011, 33 (08) : 911 - 921